Recent Updates
Recently added Catalysts
IONS Positive Sentiment

TRYNGOLZA™ (olezarsen) approved in the EU for severe hypertriglyceridemia (sHTG)

Key Takeaway: Ionis Pharmaceuticals announced that the European Commission has approved TRYNGOLZA (olezarsen) for treating severe hypertriglyceridemia in adults. This therapy is the first RNA-targeted treatment authorized in the EU for patients with fasting triglyceride levels of 880 mg/dL or higher. The approval allows its use alongside diet and other lipid-lowering therapies.

Market Sentiment Analysis

POSITIVE FACTORS

  • TRYNGOLZA is the first RNA-targeted therapy for sHTG in the EU.
  • Approval supports treatment for patients with severe hypertriglyceridemia.
  • Combination with other therapies enhances treatment options.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+3%
120-day peak, hindsight
Typical move
6.5%
average across 15 past catalysts
Cash runway
~31 mo
Minimal dilution risk
Lead asset
IONIS-FB-LRx
Phase 2 · Macular Degeneration

Full Press Release Details

CARLSBAD, Calif.--(BUSINESS WIRE)--Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced that the European Commission (EC) has approved TRYNGOLZA™ (olezarsen) as an adjunct to diet, in combination with other lipid-lowering therapies, for the treatment of adult patients with severe hypertriglyceridemia (sHTG, fasting triglyceride levels of ≥880 mg/dL [≥10 mmol/L]). TRYNGOLZA is the first and only RNA-targeted therapy authorized in the EU for adults with sHTG ≥880 mg/dL (≥10 mmol/L). The app

Frequently Asked Questions

What is TRYNGOLZA approved for?

TRYNGOLZA is approved for treating severe hypertriglyceridemia in adults.

Who approved TRYNGOLZA?

The European Commission approved TRYNGOLZA for use in the EU.

What triglyceride levels does TRYNGOLZA target?

It targets patients with fasting triglyceride levels of 880 mg/dL or higher.

Is TRYNGOLZA the first of its kind?

Yes, it is the first RNA-targeted therapy authorized for this condition in the EU.

Last updated: Nov 17, 2026